Supernus Pharmaceuticals SUPN Gross margin

Gross margin at other companies

AbbVieABBV

71.5%+0.5pp

Acadia PharmaceuticalsACAD

91.1%-0.8pp

Axsome TherapeuticsAXSM

92.6%+1.1pp

Neurocrine BiosciencesNBIX

98.2%-0.3pp

XER

Xeris Biopharma Holdings, Inc.XERS

86.6%+4.3pp

Amneal Pharmaceuticals, Inc.AMRX

39.3%+1.7pp

FAQ

What is Supernus Pharmaceuticals's gross margin?

Supernus Pharmaceuticals (SUPN) reported gross margin of 89.4% in Q1 2026.

How has Supernus Pharmaceuticals's gross margin changed year-over-year?

Supernus Pharmaceuticals's gross margin increased by 1.1% year-over-year, from 88.4% to 89.4%.

What is the long-term trend for Supernus Pharmaceuticals's gross margin?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's gross margin has grown at a -0.1% compound annual growth rate (CAGR), from 89.9% to 89.6%.

What does gross margin mean?

Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.